Clinical Research & CRO support
Define the programme before assembling the delivery model.
NovaPharm provides evidence-led programme framing and qualified specialist coordination. It does not present itself as a global full-service CRO and does not assume sponsor, investigator or competent-authority duties.
Designed for
Product owners and specialist teams facing a complex UK pathway.
The model is relevant when scientific, operational, regulatory and market-access decisions are fragmented across organisations.
- Product and dossier owners
- Biotechnology and specialty-pharma teams
- CMO and CDMO partners
- Qualified specialist service providers
Common fracture points
Where programmes lose clarity.
- 01Responsibility is assumed.
Critical ownership is implied rather than recorded.
- 02Evidence changes context.
Versions, decisions and source limitations separate across hand-offs.
- 03The UK pathway arrives late.
Market and regulatory dependencies are considered after avoidable work.
Three lanes
Scientific direction, delivery coordination and UK continuity.
Programme framing
Define the decision, evidence state, material gaps and accountable owner.
Qualified orchestration
Map specialist providers, interfaces, dependencies and escalation routes.
UK pathway continuity
Connect development choices to future regulatory and market-entry context.
Responsibility model
Three roles. One visible evidence trail.
- 01Sponsor-retained duties
The sponsor keeps its applicable legal, regulatory and oversight responsibilities.
- 02NovaPharm coordination
NovaPharm coordinates only the evidence-backed scope agreed for the programme.
- 03Qualified specialists
Appropriately qualified providers perform specialist functions under defined governance.
Quality and governance
Evidence remains attached to the decision it supported.
Responsibilities, versions, risks, escalation and approvals are preserved in a controlled programme record.
Senior judgement
Corporate, scientific and operational review remain connected.
How engagement begins
Start with a non-confidential description of the programme and the decision you need to make.
Questions
Before a programme conversation.
Does NovaPharm replace the sponsor or competent authority?
No. Responsibilities remain with the appropriately authorised and accountable parties.
Does an initial discussion establish a delivery commitment?
No. Scope, evidence, partners, responsibilities, terms and applicable permissions require separate review.
Can confidential or patient information be submitted through the public form?
No. Begin with non-confidential business context and do not submit patient-identifiable or safety-report information.